NEW YORK (GenomeWeb) — Canon Medical Systems has completed its acquisition of a majority stake in ACTmed, a Japanese joint venture established with Taiwanese molecular diagnostics firm ACT Genomics (ACTG), ACTG said today.
As part of the transaction, ACTG will transfer its clinical next-generation sequencing technology — which includes its flagship ACTOnco+ assay for determining the mutational status of solid tumors and guiding treatment selection — to ACTmed. ACTG has also agreed to support ACTmed's cancer genomic profiling operations in Japan and provide it with sequencing data analysis services.
Additional details were not disclosed.